We have recently reported enhanced preclinical anti-tumor activity of M7824, which is an innovative first-in-class bifunctional fusion protein composed of two extracellular domains of TGF β receptor II (a TGF-β “trap”) fused to a human anti–PD-L1 IgG1 monoclonal antibody [1]. This evidence concerns the gene CD274 and neoplasm.